English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Friday, May 10, 2019
Eisai Enters Into Licensing Agreement With Medac Concerning Anti-Rheumatic Agent Methotrexate Subcutaneous Injection in Japan
Eisai: Alzheimer's Clinical Trials Consortium Selects Elenbecestat and BAN2401
Thursday, May 9, 2019
エーザイとアルム、ICTを活用したヘルスケアソリューションにおける資本業務提携契約を締結
エーザイ、創薬イノベーションおよびエコシステム プラットフォーム構築の加速に向けたベンチャー投資事業を開始
Eisai and Allm Enter Into Capital and Business Alliance Agreement for ICT Healthcare Solutions
Eisai Commences Venture Investment Business Aimed at Accelerating Innovation in Drug Creation and Establishment of Ecosystem Platform
Wednesday, May 8, 2019
エーザイとUK Dementia Research Institute、認知症研究を加速する新しい博士研究員プログラムを共同で開始
Eisai and UK Dementia Research Institute Jointly Launch New Post-Doctoral Programme to Accelerate Dementia Research
Wednesday, May 1, 2019
エーザイ、「レンボレキサント」に関するPurdue社の権利を獲得し、提携を終結
Eisai Buys Out Purdue Rights to End Collaboration

Copyright © 2020 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6653 1210 | Tokyo: +81 3 6859 8575